www.health.mil US Department of Veterans Affairs www.va.gov/health US Food & Drug Administration www.fda.gov Kidney Interagency Coordinating Committee www.niddk.nih.gov/about-niddk/advisory-coordinating-committees/kuh-icc/kicc National Heart, Lung, and Blood Institute of the National Institutes of Health www.nhlbi.nih.gov National Institute of Diabetes and Digestive and Kidney Diseases of the National Institutes of Health www.niddk.nih.gov United States Renal Data System www.usrds.org American Association of Kidney Patients www.aakp.org American Society of Nephrology www.asn-online.org National Kidney Foundation www.kidney.org University of California, San Francisco, and University of California, San Francisco Center for Vulnerable Populations www.ucsf.edu University of Michigan, Division of Nephrology, Department of Internal Medicine, and University of Michigan Kidney Epidemiology and Cost Center www.med.umich.edu/intmed/nephrology **Links to nonfederal organizations are provided solely as a courtesy. Links do not constitute an endorsement of any organization by CDC, the Department of Army/ Navy/Air Force, Department of Defense, or the federal government, and none should be inferred. CDC is not responsible for the content of individual organization’s web pages. Note: This publication is not subject to copyright restrictions; duplicate and distribute copies as desired. Citation: Centers for Disease Control and Prevention. Chronic Kidney Disease in the United States, 2021. Atlanta, GA: US Department of Health and Human Services, Centers for Disease Control and Prevention; 2021. References 1. Centers for Disease Control and Prevention. Chronic Kidney Disease Surveillance System website. https://nccd.cdc.gov/CKD. Accessed 2/19/2021. 2. Kidney Disease: Improving Global Outcomes CKD Work Group. KDIGO 2012 clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney Inter. 2013;3(1)(suppl):1–150. 3. Meisinger C, Döring A, Löwel H, KORA Study Group. Chronic kidney disease and risk of incident myocardial infarction and all-cause and cardiovascular disease mortality in middle-aged men and women from the general population. Eur Heart J. 2006;27(10):1245–1250. 4. National Institutes of Health. 2020 USRDS Annual Data Report: Epidemiology of Kidney Disease in the United States. Bethesda, MD: National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases; 2020. 5. Tuot DS, Wong KK, Velasquez A, Crews DC, Zonderman AB, Evans MK, Powe NR. CKD awareness in the general population: performance of CKD-specific questions. Kidney Med. 2019;1(2):43–50. 6. Chu CD, McCulloch CE, Banerjee T, et al; Centers for Disease Control and Prevention Chronic Kidney Disease Surveillance Team. CKD awareness among US adults by future risk of kidney failure. Am J Kidney Dis. 2020;76(2):174– 183. 7. Yarnoff BO, Hoerger TJ, Shrestha SS, et al. Modeling the impact of obesity on the lifetime risk of chronic kidney disease in the United States using updated estimates of GFR progression from the CRIC study. PLoS One. 2018;13(10):e0205530. 8. American Diabetes Association. Microvascular complications and foot care: Standards of Medical Care in Diabetes—2021. Diabetes Care. 2021;44(Suppl. 1):S151–S167. 9. Astor BC, Hallan SI, Miller ER 3rd, Yeung E, Coresh J. Glomerular filtration rate, albuminuria, and risk of cardiovascular and all-cause mortality in the U.S. population. Am J Epidemiol. 2008;167(10):1226–1234. 10. Go AS, Chertow GM, Fan D, McCulloch CE, Hsu CY. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med. 2004;351(13):1296–1305. 11. Walters BA, Hays RD, Spritzer KL, Fridman M, Carter WB. Health-related quality of life, depressive symptoms, anemia, and malnutrition at hemodialysis initiation. Am J Kidney Dis. 2002;40(6):1185–1194. 12. Burrows NR, Vassalotti JA, Saydah SH, et al. Identifying high-risk individuals for chronic kidney disease: results of the CHERISH Community Demonstration Project. Am J Nephrol. 2018;48(6):447–455. 13. Stratton IM, Adler AI, Neil HA, et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ. 2000;321(7258): 405–412. 14. Adler AI, Stratton IM, Neil HA, et al. Association of systolic blood pressure with macrovascular and microvascular complications of type 2 diabetes (UKPDS 36): prospective observational study. BMJ. 2000;321(7258):412–419. 15. Parving HH, Lehnert H, Bröchner-Mortensen J, Gomis R, Andersen S, Arner P; Irbesartan in Patients with Type 2 Diabetes and Microalbuminuria Study Group. The effect of irbesartan on development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med. 2001;345(12):870–878. 1 CAUSES AND CHARACTERISTICS OF THE BURDEN OF DISEASES Estimates of the global burden of disease indicate that diseases of the kidney and urinary tract account for approximately 830,000 deaths and 18,467,000 disability-adjusted life years annually, ranking them 12th among causes of death (1.4 percent of all deaths) and 17th among causes of disability (1.0 percent of all disability-adjusted life years). This ranking is similar across World Bank regions